We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Eli Lilly and Company (LLY) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$232.77 after a previous close of US$232.18. During the day the price has varied from a low of USD231.34 to a high of USD235.385. The latest price was USD231.68 (25 minute delay). Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$232.77 |
|---|---|
| High | US$235.385 |
| Low | US$231.34 |
| Close | US$231.68 |
| Previous close | US$232.18 |
| Change | US$-0.5 |
| Change % | -0.2154% |
| Volume | 1,592,665 |
| 52-week range | US$127.0495 - US$275.87 |
|---|---|
| 50-day moving average | US$234.8874 |
| 200-day moving average | US$226.1828 |
| Target price | US$271.3 |
| PE ratio | 36.6541 |
| Dividend yield | US$3.18 (1.32%) |
| Earnings per share (TTM) | US$6.65 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $231.68
| 1 month (2021-09-23) | -0.22% |
|---|---|
| 3 months (2021-07-26) | -4.74% |
| 6 months (2021-04-26) | 23.75% |
| 1 year (2020-10-26) | 63.50% |
|---|---|
| 2 years (2019-10-25) | 110.24% |
| 3 years (2018-10-26) | 117.76% |
| 5 years (2016-10-26) | 201.82% |
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Eli Lilly and Company shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7009. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9.1 billion (£6.6 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$26.7 billion |
|---|---|
| Operating margin TTM | 28.52% |
| Gross profit TTM | US$19.1 billion |
| Return on assets TTM | 10.61% |
| Return on equity TTM | 111.03% |
| Profit margin | 22.71% |
| Book value | 7.109 |
| Market capitalisation | US$233.2 billion |
TTM: trailing 12 months
There are currently 6.4 million Eli Lilly and Company shares held short by investors – that's known as Eli Lilly and Company's "short interest". This figure is 4.3% up from 6.1 million last month.
There are a few different ways that this level of interest in shorting Eli Lilly and Company shares can be evaluated.
Eli Lilly and Company's "short interest ratio" (SIR) is the quantity of Eli Lilly and Company shares currently shorted divided by the average quantity of Eli Lilly and Company shares traded daily (recently around 2.8 million). Eli Lilly and Company's SIR currently stands at 2.26. In other words for every 100,000 Eli Lilly and Company shares traded daily on the market, roughly 2260 shares are currently held short.
However Eli Lilly and Company's short interest can also be evaluated against the total number of Eli Lilly and Company shares, or, against the total number of tradable Eli Lilly and Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eli Lilly and Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Eli Lilly and Company shares in existence, roughly 10 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Eli Lilly and Company shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eli Lilly and Company.
Find out more about how you can short Eli Lilly and Company stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Dividend payout ratio: 42.34% of net profits
Recently Eli Lilly and Company has paid out, on average, around 42.34% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.39% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 1.39% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.18 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 November 2021 (the "ex-dividend date").
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$127.0495 up to US$275.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.3111. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; MiNA Therapeutics Limited; Verge Genomics; and The Banner Alzheimer's Institute, as well as Kumquat Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
